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Retinitis Pigmentosa (RP) in the human is a progressive, currently irreversible neural degenerative dis-
ease usually caused by gene defects that disrupt the function or architecture of the photoreceptors. While
RP can initially be a disease of photoreceptors, there is increasing evidence that the inner retina becomes
progressively disorganized as the outer retina degenerates. These alterations have been extensively
described in animal models, but remodeling in humans has not been as well characterized. This study,
using computational molecular phenotyping (CMP) seeks to advance our understanding of the retinal
remodeling process in humans. We describe cone mediated preservation of overall topology, retinal
reprogramming in the earliest stages of the disease in retinal bipolar cells, and alterations in both small
molecule and protein signatures of neurons and glia. Furthermore, while Müller glia appear to be some of
the last cells left in the degenerate retina, they are also one of the ﬁrst cell classes in the neural retina to
respond to stress which may reveal mechanisms related to remodeling and cell death in other retinal cell
classes. Also fundamentally important is the ﬁnding that retinal network topologies are altered. Our
results suggest interventions that presume substantial preservation of the neural retina will likely fail in
late stages of the disease. Even early intervention offers no guarantee that the interventions will be
immune to progressive remodeling. Fundamental work in the biology and mechanisms of disease pro-
gression are needed to support vision rescue strategies.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Animal models of retinitis pigmentosa (RP) have been exten-
sively studied. However, with a couple of exceptions (Li et al., 1995;
Fariss et al., 2000; Marc et al., 2007), detailed documentation of
retinal remodeling in humans has not been coherently summa-
rized. Our goal was to assess human RP retinas in advanced stages
of remodeling and evaluate how they compare with animal models
in terms of cellular metabolism, rewiring and cell survival. We
examined the dependence of phase III (late stage) retinal remod-
eling on cone survival and document alterations in glutamine
synthetase (GS) expression in human RP.
RP is a collection of progressive degenerative diseases with
tissue-wide defects at the molecular and cellular level in natural
(Baehr and Frederick, 2009) and engineered models of retinal
degeneration (Jones et al., 2003). As of October 1st, 2015, there are
238 genes and 278 separate loci involved in retinal degenerations
(RetNet, http://www.sph.uth.tmc.edu/RetNet/). RP presents in
different forms with varying etiologies including genetic abnor-
malities in the retinal pigment epithelium (RPE) (Gu et al., 1997;
Morimura et al., 1998), ABCR gene and ATP binding cassette de-
fects (Allikmets et al., 1997a, 1997b; Cremers et al., 1998; Allikmets,
2000; Molday et al., 2000), defects in tyrosine kinase receptors
(D'Cruz et al., 2000; Duncan et al., 2003), a number of cilliopathies
and transport defects (Li et al., 2004; Yen et al., 2006), transducin
and arrestin abnormalities (Dryja et al., 1993; Sommer and Farrens,
2006; Sommer et al., 2005, 2006, 2007; Zeitz et al., 2008), muta-
tions in the machinery of rhodopsin processing and trafﬁcking
including peripherin defects (Clarke et al., 2000), defects in rod
cGMP phosphodiesterase (McLaughlin et al., 1993, 1995; Huang
et al., 1995), defects in metabotropic glutamate receptors
(mGluRs) (Dryja et al., 2005; Zeitz et al., 2005), synthetic enzymatic
defects (Vasireddy et al., 2007), and defects in genes associated
with signaling (Chen et al., 2000; Hu and Wensel, 2002, 2004; Hu
et al., 2003; Hu and Wensel, 2004; Wensel, 2008).
It is still commonly and incorrectly held that retinal degenera-
tive diseases affect only the sensory retina, leaving the neural retina
relatively unscathed. This position overlooks remodeling, a series of
changes to retinal organization that extend beyond the photore-
ceptor layer. Loss of sensory rod and cone input to the neural retina
constitutes deafferentation and the neural retina responds in thesame manner as deafferented brain (Marc and Jones, 2003; Jones
et al., 2003).
Neural retinal deafferentation results in remodeling at the
cellular level and reprogramming at the molecular level and pro-
gressive neural degeneration becomes unavoidable (Li et al., 1995;
de Raad et al., 1996; Fletcher and Kalloniatis, 1996; Fariss et al.,
2000; Machida et al., 2000; Strettoi and Pignatelli, 2000; Strettoi
et al., 2002; Jones et al., 2003; Marc and Jones, 2003; Marc et al.,
2003a, 2003b; Strettoi et al., 2003; Cuenca et al., 2004; Jones and
Marc, 2005; Jones et al., 2005, 2006; Marc et al., 2005a; Jones
et al., 2006; Pu et al., 2006; Aleman et al., 2007; Marc et al., 2007,
2008; Jones et al., 2011, Jones et al., 2012). Remodeling consists of
three major phases. Phase I is the pre-degeneration period char-
acterized primarily by early markers of photoreceptor stress. Phase
II is the period of photoreceptor loss accompanied by glial remod-
eling of the outer nuclear layer, leaving a glial seal (not a scar)
between the remnant neural retina and the remnant RPE/choroid.
Phase III is a protracted, life-long period of neural, glial and vascular
remodeling of the survivor retina involving over thirty different
modiﬁcations (Marc et al., 2003a), including neuronal cell death,
neuronal morphologic change and migration, de novo neurito-
genesis, microneuroma formation, network rewiring, altered glial
metabolism and form, and RPE invasion of the neural retina.
RP remodeling progresses differently depending on the degree
of cone survival. In cone decimating RP the phase II/ III transition
is marked by aggressive remodeling of the neural retina, including
neuronal cell death. In cone sparing RP, islands of survivor cones
somehow delay remodeling and cell death (Marc et al., 2003b;
Jones et al., 2003), even the though the survivor cones may lack
opsin expression and appear unresponsive to light (Marc et al.,
2007). However, it appears that cone sparing RP itself may be a
sub-phase that can devolve to cone decimated forms.
It should also be noted that retinal degeneration and remodeling
can result from retinal detachment (Chang et al., 1995; Lewis et al.,
1998), AMD (Sullivan et al., 2003; Marc et al., 2008; Jones et al.,
2012) or any other situation where photoreceptors are lost, espe-
cially cones. Photoreceptor loss triggers a series of phased nega-
tively “plastic” revisions to the neural retina called retinal
remodeling. In detail, remodeling events are similar to neurode-
generative events in CNS including trauma and epilepsy (Prince
et al., 2009). Fundamentally, regardless of the initiating event
Table 1
Antibodies.
Reagent SKU RRID Source Dilution
anti-L-aspartate IgG D100R AB_2341093 Signature Immunologics 1:100
anti-L-glutamate IgG E100R AB_2532055 Signature Immunologics 1:100
anti-glycine IgG G100R AB_2532057 Signature Immunologics 1:100
anti-glutathione IgG J100R AB_2532058 Signature Immunologics 1:100
anti-L-glutamine IgG Q100R AB_2532059 Signature Immunologics 1:100
anti-taurine IgG TT100R AB_2532060 Signature Immunologics 1:100
AGB B100R AB_2532053 Signature Immunologics 1:100
anti-arginine IgG Marc Laboratory 1:100
anti-GABA IgG YY100R AB_2532061 Signature Immunologics 1:100
anti-GS IgG 610517 AB_397879 BD Biosciences 1:50
anti-CRALBP IgG NA AB_2314227 Gift of Dr. Jack Saari 1:400
anti-rod opsin 1D4 AB_2315015 Gift of Dr. Robert Molday 1:4000
anti-cone opsin AB5405 AB_177456 EMD Millipore 1:1000
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associated forms), the subsequent retinal changes and apparent
plasticity result in revisions to neuronal morphology and organi-
zation through neuritogenesis and cell migration, reprogramming
of gene expression, protein expression, glutamate channel function,
synaptic and possibly gap-junctional connectivities. The negative
implications of these changes for rescue of vision are substantial
and must be addressed if vision rescue strategies are to succeed.
2. Materials and methods
2.1. Human tissue
Exploring the metabolism of small molecules requires rapid
access to eyes for ﬁxation post-mortem. Retinal samples RP1 and
RP2 from 2 human donors with a diagnosis of RP were collected
within 3e5 h post-mortem. Some samples were incubated with the
excitation marker 1-amino-4-guanidobutane (AGB) with and
without ionotropic glutamate receptor (iGluR) agonists (Marc,
1999b, 1999a; Marc and Jones, 2002). Samples of 4 normal hu-
man subjects were included for controls. Portions of every eye
collected for histological purposes were prepared and processed for
light and transmission electron microscope (TEM) imaging. For
CMP, eyes are immersion-ﬁxed overnight in buffered 2.5% glutar-
aldehyde, 1% formaldehyde, resin embedded and serially sectioned
at 70e250 nm (Marc et al., 1995). Normal and RP samples ranged
from subjects ranging in age from 30 to 80 years. RP tissues were
obtained from two sources: The Foundation Fighting Blindness
Retina Donor Program, Stanford University and the University of
Utah Lions Eye Bank. Genotyping of donors was not available and
the mutations involved are unknown. Institutional approval for use
of human eyes was obtained from the University of Utah and
Stanford University and followed the tenets of the Declaration of
Helsinki. All retinal tissues and data were de-identiﬁed in accor-
dance with HIPPA Privacy Rules.
2.2. Primate tissue
Eyes from 1 adult male and 1 adult female olive baboons (Papio
anubis) were obtained during necropsy from the Southwest Foun-
dation for Biomedical Research (San Antonio, TX). Anesthesia and
euthanasia conform to institutional animal care and use authori-
zations and the ARVO Statement for the Use of Animals in
Ophthalmic and Visual Research.
2.3. OCT
Enucleated globes with the anterior segment removed weresubmerged post-ﬁxation in a large scintillation chamber ﬁlled with
normal saline for high resolution mapping and correlation with
histological/CMP analysis. High resolution scans were performed
with a Heidelberg Spectralis, OCT Plus (3 mode) w/BluePeak Im-
aging was performed on regions of interest and data saved with
landmarks. Globes were then removed, portions corresponding to
regions imaged by OCT were trephined, and processed for CMP.
Since the eyes were post-mortem, long collection times could be
used with 391 frames per scan. Frames were exported as png
channels and imported into Osirix DICOM viewing software http://
www.osirix-viewer.com/AboutOsiriX.html for re-slicing to explore
and ﬁnd the optimal region for correlationwith histological images.
Once precise regions were identiﬁed, IR-Tweak, part of the NCR
toolset https://www.sci.utah.edu/download/ncrtoolset.html was
used to register the OCT images to the histological images.2.4. Computational molecular phenotyping (CMP)
Tissues were probed with IgGs selective for individual small or
macro molecules (aspartate (D), arginine (R), glutamate (E), glycine
(G), glutathione (J), glutamine (Q), taurine (t), GABA (g), CRALBP,
rod opsin (1D4), cone opsin (rg-opsin) or GS (Table 1), visualized
with secondary antibodies conjugated to 1.4 nm gold, followed by
silver intensiﬁcation (Marc et al., 1995).
Images were captured as 8-bit high-resolution (243 nm/pixel)
images (Marc and Jones, 2002), mosaicked, and registered with ir-
tweak https://www.sci.utah.edu/download/ncrtoolset.html into
large image databases. Cell classiﬁcation was performed on N-
dimensional (N-space) monochrome images via k-means or ISO-
DATA clustering (Marc et al., 1995; Marc and Cameron, 2002; Marc
and Jones, 2002) using PCI Geomatica (PCI Geomatics, Inc.) for pixel
based clustering and mask generation into theme maps. Detailed
theme map generation ﬁrst involves production of raw classi-
fication theme maps (Marc et al., 1995; Kalloniatis et al., 1996),
which is the mathematical division of regions into statistically
separable classes based on multiple channel inputs. Adobe Photo-
shop (Adobe, San Jose, CA) was used for ﬁnal image generation. For
display only, raw data channels are linearly contrast-stretched over
a 30e220 pixel value range and sharpened with unsharp masking.
Molecular signals were visualized as selected rgb maps encoding
three molecular signals as red, green, and blue, respectively, e.g.,
g.G.E / rgb which assigns g-aminobutyric acid, glycine and L-
glutamate to red, green, and blue color channels, respectively.
Monochrome images are density mapped and rgb images intensity
mapped (Marc et al., 1995). Both high and low magnification EM
images montages are captured digitally as 12-bit monochrome
channels and assembled into large mosaics (Anderson et al., 2009).
Fig. 1. CMP of 77 year old normal human male (A, B) and primate (C,D). A. g.G.E./ rgb mapping of human peripheral retina from a 77 year old male. Inhomogeneity in the small
molecule signals of the RPE indicated by arrows in B. Small druse, asterisk. Mild elevation of GABA in the Müller cells. B. t.Q.E/ rgb mapping reveals Müller cells in yellow. Mild
postmortem elevations of glutamine and taurine in Müller cells. RPE heterogeneity (arrows). C. Normal macaque retina, g.G.E./ rgb mapping. No RPE heterogeneity. No elevation
of GABA in Müller cells. D. Normal macaque retina, t.G.E./ rgb mapping. No RPE heterogeneity. No abnormal elevation of glutamine or taurine in Müller cells. Scale ¼ 40 mm.
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Tissues were postﬁxed in 1% buffered osmium tetroxide, fol-
lowed by resin embedding and thin sectioning. Large scale trans-
mission electron microscopy was then performed, creating EM
mosaics as previously described on 90 nm lead-stained sections on
single-slot grids (Marc et al., 2012).2.6. Imaging terminology
The convention for display of image data (Marc et al., 1995,
2005b) in this text and ﬁgures is deﬁned by the use of single-
letter biochemical codes for amino acids (e.g. G glycine, E gluta-
mate, Q glutamine, etc …) and augmented by notations for non-
protein amino acids and other small molecules (B AGB, t taurine,Fig. 2. Fundoscopic images of a 67 year old normal human retina (HS1) in A and a fundoscop
to death. The fundoscopic image of RP1 demonstrates a pale fundus, optic nerve atrophy, ag GABA). Color images are rendered as true-color rgb-mapped
images where each molecule is mapped to a channel. For example
g.G.E / rgb implies that GABA signals are mapped to the red
channel, glycine signals to the green channel and glutamate signals
to the blue channel.3. Results
Progressive rod-speciﬁc degeneration leads to complete elimi-
nation of rods and rod signaling and often cone decimation. In
cone-sparing forms of RP, there is extensive survival of substantially
altered cones until late in the disease, whereupon complete topo-
logical or structural remodeling occurs as well as extensive
neuronal death. The presence of survivor cones grossly stabilizes
the remodeling process, and preserves iGluR signaling in coneic image from an RP donor (RP1), then aged 58 when imaged in 1991 in B, 20 years prior
nd vessel attenuation. This retina provided the tissue for sample RP1.
Fig. 3. Backlit extended depth-of-focus view of sample RP2 retina, visualizing pigmented bone spicules invading the neural retina. Spicules appear to ﬁll the spaces between cells
and function as highways or facilitated pathways for migration of other cell classes that ultimately alter the topology throughout the retina. Scale ¼ 200 mm.
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in the neural retina demonstrate neurite sprouting, cell migration,
and reprogramming of GluR expression (Marc et al., 2007; Lin et al.,
2012a, 2012b). Additionally, marked reduction in glutamine syn-
thetase (GS) expression occurs in retinal degeneration as remod-
eling progresses. By late stages of retinal degenerative diseases, GS
expression is largely absent. Remarkably, metabolic reprogram-
ming revealed by CMP shows chaotic patterns not predicted byFig. 4. A. Hypertrophic blood vessel adjacent to the inner limiting membrane invested by pi
retina in the former ganglion cell layer, Scale ¼ 3 mm. C. A remnant RPE cell invading the neu
intracellular debris, pigment granules surrounding vascular elements. Scale ¼ 2 mm.changes in GS levels (Pfeiffer et al., 2016), in press. Finally, we see no
evidence that remodeling ever stops.
Normal human tissues were harvested within 3e5 h s post
mortem for analysis and comparison with RP samples. Normal
human retina was identical to primate retina with the exception of
minor ischemic changes observable in human tissues from post-
mortem changes. This occurs in both normal and RP retinas. Al-
terations in small molecule patterns in retinal post-mortemgmented RPE processes. Scale ¼ 15 mm B. RPE pigment granules deep within the neural
ral retina. Scale ¼ 9 mm. D. An inset from C showing detail of the pigment granules and
Fig. 5. CMP and excitation mapping in human sample RP2. A. g.G.E/ rgb mapping. B. G.AGB.E/mapping. The AGB signal is induced by activating iGluRs with 25 mM kainic acid.
C. Classiﬁed retinal neurons, revealing ON cone bipolar, OFF bipolar, rod bipolar, GABAergic amacrine, glycinergic amacrine, horizontal and ganglion cells. Retinal bipolar cell classes
in normal retina should approximate 33% each for ON, OFF and rod bipolar cell classes. However, in retinitis pigmentosa, excitation mapping reveals extensive class switching of rod
bipolar cells from ON to OFF subclasses as manifested by iGluR functional display D. Scale ¼ 60 mm.
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which causes clear banding in the IPL, and increases in GABA
concentrations in Müller cells. Fig. 1 shows the normal overall to-
pology, structure and lamination of the human retina, and dem-
onstrates minor changes in small molecule levels 1.5 h s post
mortem. For unknown reasons, post-mortem, ischemic retina re-
sults in small molecule signals being better preserved in the pe-
ripheral retina than in central retina. Rapid ﬁxation in the macaque
retina (Fig. 1C, D) captures normal metabolic signatures with no
signs of ischemia (Kalloniatis et al., 1996). We speculate that dif-
ferences in vascularization of the central vs. peripheral retina or
differences in metabolic demands of central vs. peripheral retina
may inﬂuence the signals we observe post-mortem.
Aside from alterations in GABA content in ischemic retina,
normal aged human retinas (Fig. 1A,B, sample HS1) show the ex-
pected retinal stratiﬁcationwith no signs of remodeling or cell loss.
However, aged human RPE often shows small molecule heteroge-
neity in the RPE that we call “bricking”, especially in the glutamine
and taurine channels suggestive of changes due to aging, oxidative
stress or even potential indications of early age-related maculardegeneration (AMD). However, heterogenous RPE signals are
common in our samples and suggest that RPE stress is widespread
in humans with age, independent of any disease diagnosis.
Importantly, Fig. 1C, D demonstrates CMP results from a macaque
retina harvested immediately post-mortem, demonstrating normal
signatures, lamination, and cell layer thickness with g.G.E / rgb
mapping in C and t.Q.E/ rgbmapping in D revealing normal small
molecule levels without ischemic changes. Additionally, non-
human primate retinas never show bricking in the RPE, but rather a
homogenous t.Q.E signature across the entire retina.3.1. RP human retina, fundoscopy
Human RP retinas are dramatically different from normal
human retinas. Fig. 2 shows fundoscopic exams from an 67yo
normal male (Sample HS1) and an 77yo male (Sample RP1) diag-
nosed with RP at age 25. Fortunately, we have some medical re-
cords from donor RP1 giving insight into the progression of the
disease. At age 31 patient RP1 had bilateral 20/30 acuity, but a wide
ring scotoma sparing only a central tunnel spanning 10e15 with
Fig. 6. Sparse cone sparing in sample RP2. A. g.G.E / rgb mapping showing high blue glutamate signals in a cluster of cones (square) and isolated cones projecting into the
subretinal space (arrows). B. t.Q.E/ rgb mapping showing characteristic magenta cone and yellow-gold Müller cell signatures. C. Square Inset from A. D. Square inset from B. E.
Rectangle inset from in A showing excessive glycine þ neuritogenesis in the outer retina. Asterisk in B demonstrates onset of Müller glial seal. All scales ¼ 42 mm.
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marked vascular attenuation and peripheral bone spicule
pigmentation, indicative of advanced remodeling. He retainedFig. 7. g.G.E/mapping in a peripheral region of retina from Sample RP2. This region is devo
amacrine cells emigrating into the remnant sub-retinal space. Scale ¼ 42 mm.moderately good visual acuity until age 55 (bilateral 20/80 acuity)
and visual ﬁelds constricted to 10. His last ophthalmological exam
at age 66 showed end-stage RP with dense bone spiculeid of remnant rods or cones. The area in the rectangle shows GABAergic and glycinergic
Fig. 8. Retina from late phase III remodeling in sample RP1. A, OCT of the area of retina subserved by the red stripe, registered to the histology shown in B-E. B. g.G.E/ rgb mapping,
showing nearly complete loss of bipolar and ganglion cells. C. t.Q.E/ rgb mapping revealing that Müller cells in yellow now dominate the retina. D. GFAP.CRALBP.R/ rgb mapping.
E. Phase contrast image showing pigment granules around vascular elements and in the neural retina. F. Backlit image of the 3 mm biopsy punch. G. OCT of the area of retina
subserved by the blue stripe, registered to the histology shown in H and I. H. g.G.E./ rgb mapping. I. GFAP. CRALBP. J./ rgb mapping. Scales A-E, G-I ¼ 100 mm. Scale, F ¼ 2 mm.
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hand-motion at 3 feet in OS. By age 77, the fundus showed the high
pallor characteristic of very late stage RP.3.2. Pigmented bone spicules, imaging
Pigmented bone spicules are a common ﬁnding in RP. They are
accumulations of pigment granules from the RPE processes that
have invaded the neural retina and often surround blood vessels
(Milam et al., 1998). Many processes extend from the internal
limiting membrane, through the external limiting membrane and
into the remnant sub-retinal space (Fig. 3). Fig. 4A demonstrates a
hypertrophic blood vessel surrounded by RPE processes containing
pigment granules. Fig. 4B demonstrates similar processes
traversing the neural retina. These pigment granules resemble
those found at the top of the retina by the remnant RPE layer seen
in Fig. 4C and the inset D derived from remnant RPE cells being
pulled down into the neural retina (Fig. 4C, D) and not the larger
caliber, round pigment granules associated with vascular pigment.3.3. Human retina, CMP (Mid-stage RP)
As in animal models of RP (Jones et al., 2003), such as the P347L
transgenic rabbit model of autosomal dominant, cone sparing RP
(Jones et al., 2011, 2012), human RP progresses through phases I-II-III (Jones and Marc, 2005; Jones et al., 2005; Marc et al., 2005a,
2007; Jones et al., 2012). Early neural plasticity begins in phase II
prior to evidence of large scale histological alterations in the neural
retina (Marc et al., 2007; Jones et al., 2011). Obtaining samples of
phase I and early phase II human RP is difﬁcult, especially since
different genotypes progress through phases I and II at different
speeds. However, cone-sparing RP patterns the retina into islands
of decimated phase III retina in a sea of spared late phase II retina,
with graduated transition zones. Patient RP2, with aggressive,
presumed autosomal recessive RP and limited visual ﬁelds (Fig. 5)
showed late phase II remodeling and reprogramming characteristic
of cone-sparing RP, as ﬁrst reported in Marc et al., 2007. More
detailed analysis shows neuronal remodeling, apparent from the
glycine signal in Fig. 5A (g.G.E / rgb) where aberrant neuronal
sprouts from the glycinergic amacrine cells can be seen in the outer
plexiform layer.
Reprogramming also begins in late phase II retinas, even in the
presence of survivor cones. In normal primate tissues, expected
retinal bipolar cell proportions should bez 30% ON cone, 40% OFF
cone, and 30% rod bipolar cells (Marc et al., 2007). Marc et al. (2007)
also showed that both mouse and human rod bipolar cells switch
their glutamate receptors after losing rod input and become OFF
bipolar cells. Jones et al. (2011) demonstrated that the rabbit RP
model does the same. In a reanalysis of a different regions of human
RP from retina RP2, excitation mapping with AGB in response to
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rod bipolar cells to an OFF pharmacology, again despite the pres-
ence of cones. Classifying retinal cells based on small molecule
signatures (Fig. 5C) allows them to be segmented into ON cone
bipolar, OFF cone bipolar, rod bipolar, GABAergic amacrine, glyci-
nergic amacrine, horizontal and ganglion cells and highlights the
increase of OFF signals that correspond to a loss of normal rod BCs
(Fig. 5D).
The spatial heterogeneity in cone-sparing and cone-decimated
regions can be visualized in a single human retina. Cone sparing
in late phase II human RP, (Figs. 5 and 6) duplicates phase II
remodeling observed in the 10 month old Tg P347L rabbit retina, a
large eye model of human cone-sparing RP where most rod pho-
toreceptors were lost in a regional distribution (Jones et al., 2011).
Even though the retina has not moved into full scale phase III
remodeling, it is clear that aberrant neuritogenesis is beginning
(Fig. 6E).
Müller cell metabolism also begins to shift in late phase II in a
remarkable way. Rather than a wholesale change in metabolic
signatures of all Müller cells, individual Müller cell signatures begin
to alter, even when immediately adjacent to normal Müller cells.
This Müller cell reactivity and indications of morphological alter-
ation can precede cone photoreceptor loss. But after complete
photoreceptor loss, large-scale revision and topological restruc-
turing of the retina occurs. Extensive Müller cell hypertrophy then
occurs, coalescing neighboring Müller cells into large vertical glial
columns, and formation of the distal seal begin to segment the
retina into irregular domains that appear poorly connected inFig. 9. ISODATA clustering of retinal cell classes. A. In normal primate retina lamination is
ganglion cell layer GCL, optif ﬁber layer, OFL, inner limiting membrane ILM). The IPL is z 40
remodeling clearly disrupting normal lamination of the retina. The IPL and GCL are essentianimal models (Jones et al., 2003). Among the severe remodeling
defects found in animal models is the emigration of survivor neu-
rons into the remnant sub-retinal space. This occurs in the human
RP retina as well (Fig. 7).3.4. Human RP retina phase III remodeling (CMP)
Sample RP1 demonstrates severe neural retina remodeling,
including a complete loss of the normal topology and stratiﬁcation.
Fig. 7 demonstrates g.G.E / mapping in a peripheral region of
retina from Sample RP2 devoid of any remnant rods or cones, but
also showing dramatic GABAergic and glycinergic amacrine cells
emigrating out of the neural retina. Fig. 8 shows CMP images
directly correlated with post-mortem OCT imaging of a 3 mm bi-
opsy punch of human RP retina. Scaling of the OCT data with his-
tology at this scale is not very informative other than as a
demonstration of what current clinical imaging can resolve in end
stage RP. While it is not possible to identify any normal cells or
layering once the normal lamination of the retina is lost in end-
stage RP, OCT results in earlier stages of retinal degeneration are
more feasible as shown by (Pinilla et al., 2015) with the P23H rat. In
stage III, Müller cells and large zones of unknown cells now
dominate the remnant retina. There is no evidence of functional
neural retina, particularly if the retina is classiﬁed and segmented
into normal (Fig. 9A) and advanced RP, well into phase III (Fig. 9B)
demonstrating clear disruption of the normal structure of the IPL
and GCL.precise (outer plexiform layer, OPL; inner nuclear layer, INL; inner plexiform layer IPL,
mm thick B. Sample RP3 (image portion republished from Jones et al., 2003) showing
ally gone. Scale ¼ 40 mm.
Fig. 10. A near horizontal section through the Müller cell end feet revealing metabolic instability. A. t.J.E./ rgb. B. GS.t.Q/ rgb. Scale ¼ 200 mm.
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CanMüller cells in the remodeling retina support normal retinal
metabolism, including neurotransmission, reactive oxygen species
regulation and carbon skeleton recycling? Previous CMP of Müller
cells in rodent models of RP and AMD showed signiﬁcant increase
changes in glutamine content upon transitioning into phase III with
formation of the distal glial seal (Marc et al., 2008; Jones et al.,
2011). Further, it was possible to capture evidence of early meta-
bolic dysregulation in phase II while photoreceptors were still
present (Jones et al., 2011). This same early drift in metabolic sig-
natures occurs in human RP (Figs. 6 and 11B).
In analyses of human retina where zones of complete phase III
retina are ﬂanked by late phase II retina containing patches of
survivor cones, the presence of the glial seal in phase III areas is
marked by both a paradoxical decrease in GS levels (Fig. 10B,
Fig. 11C) and an increase in glutamine (Fig. 8C, Figs. 10 and 11B) in
the same cells. Thus, the change in glial metabolism observed in
animal models is mimicked precisely in human RP. In detail how-
ever, the time course of metabolic variation reveals transient
upregulation of GS expression in stressed phase II Müller cells,
followed by collapse in expression as Müller cells begin to form the
distal seal in phase III (Fig. 11). But animals models of RP are short-
lived and we did not know whether the metabolic change associ-
ated with the transition to phase III was an end point. Analysis oflate stage human RP suggests not. Rather, Müller cell metabolic
proﬁles diverge into a chaotic assembly of unrelated signatures
(Figs. 10 and 11) with uncorrelated variations in taurine, glutamine,
glutathione, glutamate and GS. This suggests that there is no single
path to metabolic variation in Müller cells and the late phase III
Müller cell cohort is unlikely to support normal metabolic ho-
meostasis in the RP retina. Interestingly, GS expression then begins
to decline and by the latest, terminal stage of retinal degeneration,
GS expression is almost completely undetectable (Fig. 11C).
4. Discussion
4.1. Retinal degeneration and remodeling in the human retina
Retinal degeneration is a primary degenerative process that
devolves to retinal remodeling, a progressive neurodegeneration
encompassing a spectrum of molecular, cellular and tissue-level
pathologies. One of our key questions has been the degree to
which human RP mimics the events described in many animal
models. We use CMP as a tool that can be used on curated legacy
samples of tissues to reveal metabolic states deﬁned by a combi-
nation of small molecules and CMP-compliant protein markers. In
instances where live human RP retina becomes available, excitation
mapping with AGB allows rapid proﬁling of neural activity. These
techniques have allowed us to show that human retina remodels in
Fig. 11. A two regions of human RP retina, stacked, probed and registered in serial sections for CRALBP, GS, GFAP in A, t.Q.E., B. The isolated GS channel is shown in C. All three panels
demonstrate inhomogeneous levels of GS expression occurring in human RP in response to retinal degeneration and subsequent retinal remodeling. Before all photoreceptors die
off, GS increases in concentration only to disappear in regions where Müller cells are engaging in seal formation. Scale ¼ 200 mm.
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remodeling in cone decimating disease which leads to extensive
loss of neurons, reorganization of the retina into chaotic tissue
patterns and glial metabolic reprogramming that appears incom-
patible with homeostatic functions of retina.4.2. Retinal remodeling is negative neural plasticity in the adult
retina
In natural models of retinal degenerations (Baehr and Frederick,
2009), trauma such as retinal detachment (Chang et al., 1995; Lewis
et al., 1998), toxin exposure (Peichl and Bolz, 1984), or any of the
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et al., 2001; Baehr and Frederick, 2009) can trigger remodeling.
Regardless of cause, if photoreceptor loss deafferents the neural
retina, it induces negative plastic remodeling of the neural retina
(Jones et al., 2003; Marc and Jones, 2003; Marc et al., 2003b; Jones
and Marc, 2005; Jones et al., 2005; Marc et al., 2005a, 2007, 2008;
Jones et al., 2011, 2012). The progression of retinal remodeling is
similar to the negative plasticity that occurs in central nervous
system (CNS) pathologies like physical trauma (Harel and
Strittmatter, 2006), epilepsy (Morimoto et al., 2004) and other
forms of CNS deafferentation such as Alzheimer's disease
(Anderton et al., 1998) and spinal injury (Sugimoto et al., 1990). The
neural responses that ultimately result in negative plasticity and
remodeling constitute substantial impediments to rescue strategies
of all types.
Retinal remodeling is not unique to RP disorders as other genetic
and environmental diseases like AMD (Sullivan et al., 2003; Jones
et al., 2012) as well as insults including trauma and retinal
detachment (Lewis et al., 1998) also induce this negative plasticity
which results in neuronal rewiring and reprogramming that in-
duces alterations in gene expression (Hackam et al., 2004), de novo
neuritogenesis (Li et al., 1995) as well as formation of new circuitry
and novel synapses in microneuromas (Jones et al., 2003; Marc and
Jones, 2003; Marc et al., 2003a). These changes are likely creating
corruptive circuitry in nominally, bipolar cell populations through
alterations in the connectivities of dendritic trees and supernu-
merary axons (Marc et al., 2007). It is likely that corruption of
neural connectivities in other retinal cell classes also occur.
4.3. Retinal degeneration and remodeling occurs in phases
Retinal remodeling occurs in phases: In phase I, photoreceptor
stress initiates early remodeling& reprogramming events as well as
metabolic alterations in Müller glia. In phase II, microglia and RPE
cells become involved and Müller glia begin to hypertrophy. Outer
nuclear layer (ONL) ablation also occurs in phase III and cell stress
pathways are engaged while Müller cells begin sealing the retina
off from the choroid. In phase III, de novo neurite formation,
rewiring and neuronal death start a process that continues to
progress with neuronal translocation and massive restructuring of
the retina (Jones et al., 2003; Marc and Jones, 2003; Marc et al.,
2003b, 2004; Jones and Marc, 2005; Jones et al., 2005; Marc
et al., 2007, 2008; Jones et al., 2011, Jones et al., 2012).
Fundamentally, this process leaves open questions of precisely
when retinal plasticity and remodeling begins and, perhaps more
importantly, when and if they ever end. These questions have im-
plications for when and how interventional therapies should be
implemented. However, it will be difﬁcult to track the earliest
stages of retinal plasticity given current clinical imaging method-
ologies. We simply do not have enough resolution with current
clinical OCT technologies to distinguish this early plasticity. Even
recent advances in fundus autoﬂuorescence will only visualize later
stages of disease processes, far later than phase I retinal remodel-
ing, particularly in the periphery where RP will be most involved.
Indeed, there we demonstrate that retinal remodeling in the hu-
man adult retina begins early, before clinically observable signs
become apparent via fundoscopic imaging or behavior or tradi-
tional histological analysis reveal it (Jones et al., 2011).
Clinical sequelae depend upon the form of RP involved, but
commonly, the initial rod/cone dystrophies manifest with com-
plaints about nyctalopia beginning in the teens or early 20's and
changes in the electroretinogram (ERG) can often be observed prior
to fundoscopic ﬁndings (Young et al., 1996). This reveals something
fundamental: Photoreceptor function is altered or impaired prior to
photoreceptor cell death and clinical fundoscopic ﬁndings or evenbefore light histological analysis become evident. By the time the
classic fundoscopic image of pigmented bone spicules appears in
human patients, retinal degeneration is advanced with hypertro-
phic Müller cells, acting as highways for neuronal translocation as
well as pigment translocations into the inner retina from the RPE
(Jones et al., 2003). At this point, neuronal populations have been
lost and the image processing substrate of the neural retina is
forever altered.
4.4. Retinal remodeling alters the molecular identity of retinal
neurons
Alternations to neurons in the retina manifest themselves
morphologically, but also in alterations that are detectable at the
molecular level. Examining just the dendritic loss from bipolar cells
would reveal a number of proteins that are impacted from gap
junctions to iGluR and cytoskeletal elements. Indeed, many hy-
pothesis have been constructed attempting to explain dendritic
arbor remodeling after loss of afferent excitatory activity
(Turrigiano and Nelson, 2000), which could result from changes to
a variety of molecular alterations including early immediate genes
(Byers et al., 2000), extracellular matrix proteins (Johnson and
Anderson, 2004) and glutamate receptors (Gazzaley et al., 1997;
Marc et al., 2007; Jones et al., 2011; Lin et al., 2012a, 2012b) as
well as exciting work in the roles of microglia (Almasieh et al., 2012;
Roh et al., 2012) in the degenerative process. Additionally, a number
of groups have explored reduced neurotransmission and ectopic
synaptic formation (Ball et al., 2003; Haeseleer et al., 2004;
Mansergh et al., 2005; Chang et al., 2006; Bayley and Morgans,
2007) in various mutants. Yet despite some localized recording of
degenerate retina indicating aberrant processing (Homma et al.,
2009) and retinal output from GCs (Sekirnjak et al., 2011), as well
as efforts to examine gene expression in early ectopic synapto-
genesis (Michalakis et al., 2013), very few studies have examined
how these changes impact the precise retinal circuitry and function
of the neural retina in degenerative disease in any of the various cell
classes, despite over a decade of work from labs studying retinal
degeneration and remodeling. That said, substantial efforts are
being made to examine how gap junctional coupling is altered
(Ivanova et al., 2015a, 2015b) as well as exploring how retinal
processing pathways undergo change as a result of degeneration
(Yee et al., 2014; Ivanova et al., 2016).
4.5. Retinal reprogramming
Because we were able to get some RP samples (RP2) within 4 h
post-mortem, we were able to explore the glutamate mediated
signaling in RP retina through excitation mapping with AGB (Marc,
1999a, 1999b; Marc and Jones, 2002; Marc et al., 2005b, 2007). AGB
permeates ionotropic glutamate gated AMPA, KA and NMDA re-
ceptors/channels and mGluR6-gated channels, revealing activity in
those neuronal populations.
Human and non-human primate retina exhibits three major
classes of bipolar cells: ON cone bipolar cells, OFF cone bipolar cells
and rod bipolar cells (Wassle and Boycott, 1991). The use of CMP
demonstrates two major classes of bipolar cells, ON cone bipolar
cells and a complex of rod and OFF cone bipolar cells (Kalloniatis
et al., 1996; Marc et al., 1998). Activity probing of glutamate chan-
nel permeation with AGB contributes physiological response pro-
ﬁles to neurons identiﬁed through CMP as well as acting as an
additional discriminant (Marc, 1999b, 1999a; Marc and Jones,
2002), that recapitulates data from physiological experiments
showing that ON bipolar cells utilize metabotropic GluRs and are
thus KA insensitive (Slaughter and Miller, 1981, 1983; Karschin and
Wassle, 1990; Yamashita and Wassle, 1991; Sasaki and Kaneko,
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proﬁles to KA administration and label strongly with AGB whereas
rod bipolar cells show no labeling after KA administration (Marc,
1999a). Therefore, application of KA in the presence of AGB, al-
lows visualization of neuronal classes including bipolar cell classes
presenting with AMPA/KA receptor pharmacological phenotypes
(Marc, 1999a).
Human RP retina shows identical ﬁndings observed in the
mouse (Marc et al., 2007), and the rabbit (Jones et al., 2011),
exhibiting physiological response proﬁles that demonstrate
phenotypic revisions of bipolar cell classes in response to photo-
receptor cell death. These proﬁles suggest that mGluR6 and iGluR
channel expression has been radically altered in the degenerate
retina, revealing a common biological motif in response to neural
deafferentation that effectively reprograms the remaining retina by
converting rod and ON bipolar cells to an OFF bipolar cell pheno-
type (Fig. 5). These ﬁndings hold in all instances of cone sparing
animal models of RP and are consistent with immunohistochemical
work by Cuenca et al. (Cuenca et al., 2014) and work examining the
rapid alterations of mGluR post photoreceptor ablation (Lin et al.,
2012b; Dunn, 2015). Additional work in the rd1 mouse shows
that oscillatory activity may transferred from the ON to OFF path-
ways via a glycergic synapse (Poria and Dhingra, 2015).
The ﬁnding of altered bipolar cell populations implying a Rod
BC / OFF BC functional transition from rod OFF-like bipolar cell
phenotypes in mouse models of RP, human RP and in a large eye
model of autosomal dominant RP, the P347L rabbit (Jones et al.,
2011) indicates a common mechanism responsible for maintain-
ing bipolar cell identity and a common path of reprogramming
from loss of rod photoreceptors. It is important to note that these
changes occur before bipolar cell connections are lost and certainly
before signiﬁcant histopathologic changes in the ONL.
It has been shown that some retinal neurons including bipolar
cells exhibit spontaneous membrane oscillations suggesting that
cone bipolar cells become intrinsically active (Borowska et al.,
2011). These oscillations appear to be light-independent spiking
in ON and OFF ganglion cells in the rd1 mouse model (Stasheff,
2008; Menzler and Zeck, 2011; Margolis et al., 2014). It should be
noted that self-signaling in the absence of photoreceptors in the
rd1mouse includes a large spectrum of amacrine and ganglion cells
(Marc et al., 2007) and the presence of well preserved regions of the
retina in RP prior to phase III remodeling does not mean the retina
functions normally.
4.6. Altered metabolism of Müller cells and retinal topological
restructuring
Müller cells are responsible for recycling of carbon skeleton el-
ements of the retina and, via their uniquely high expression of GS,
appear essential for the recycling of transported glutamate into
glutamine (Pow and Crook, 1996), a major precursor for both
excitatory and inhibitory neurons (Marc, 2004). Müller cell meta-
bolic status appears to be exquisitely sensitive to photoreceptor cell
stress. In animal models, Müller cells demonstrate metabolic al-
terations prior to photoreceptor cell loss (Jones et al., 2003; Marc
and Jones, 2003; Marc et al., 2003a; Jones and Marc, 2005; Jones
et al., 2005, 2011, 2012) and may reveal potential targets of inter-
vention important in preserving retinal topology and function.
While Müller cells exhibit metabolic alterations prior to obvious
photoreceptor cell loss, they also undergo a series of morphological
transformations after cone photoreceptors are lost, ultimately
forming a seal between the remnant neural retina and the remnant
choroid and also form conduits for the translocation of migrating
neurons. Themechanism forMüller cell hypertrophy is unknown as
are mechanisms for migration of cell classes along Müller cellcolumns in advanced remodeling.
4.7. Remodeling alters circuitry to form unknown circuit topologies
Considering the changes to retinal topology in late stage RP,
there is a signiﬁcant question as to the fates of thez80 individual
cell classes in the retina as well as their connectivities. It is clear
that given the alterations in retinal neuronal cell classes shown
here and previously documented (Marc et al., 2007; Jones et al.,
2011), along with alterations in glutamate receptors (Lin et al.,
2012b; Dunn, 2015) and alterations in electrical activity of bipolar
cells (Borowska et al., 2011) and ganglion cells (Stasheff, 2008;
Menzler and Zeck, 2011; Margolis et al., 2014), retinal function as
well as circuitry and glutamate channel expression are clearly
compromised early in the retinal degenerative process. By late
phase III, networks involving major cell classes such as the AII
amacrine cell (Marc et al., 2014) will be dramatically altered as
neurons die, though the precise timing and sequence of cell class
loss and circuitry alterations are not known. Furthermore, given the
changes in retinal circuitry, there are implications for downstream
changes in CNS in response to lesions (Boucard et al., 2009; Aguilar
et al., 2010).
4.8. Summary of the progression to non-functional retina
RP involves extensive remodeling that ultimately destroys the
organization of the retina to such an extent that many cell classes
are no longer remaining by advanced stages of the disease. Stan-
dard histology does not segment or quantify the extent of remod-
eling, but CMP demonstrates the extent of alterations observed in
human retina compared to normal human retina or young primate
retina (Fig. 9). For simplicity sake, the photoreceptor cell classes
were omitted from the normal primate retina in Fig. 9, but the
remaining amacrine, bipolar, horizontal, ganglion, Müller, vascular
and RPE cells are shown after CMP and image based clustering,
revealing the dramatic alterations in topology compared with a
normal primate retina. At this stage, the late phase III RP retina has
no recognizable features of a normal retina and former INL cells in
this region have migrated down into the remnant ganglion cell
layer or up to the distal retina.
4.9. Impact of remodeling on therapeutics
Retinal remodeling has substantial impact on potential thera-
peutic interventions. Phase I and II retinal remodeling alters gene
expression and the neuronal class switching/reprogramming re-
sembles normal plastic behavior observed in CNS which might be
amenable to the right therapeutic interventions. Müller cell meta-
bolic changes, glial seal formation, RPE bricking, vascular remod-
eling are all potential complications that may or may not be
amenable to treatment. However, by the time phase III remodeling
happens with rewiring, neuritogenesis, Müller seal formation,
microneuroma formation, neuronal migration, and cell death,
therapeutic interventions to the surviving retina are likely impos-
sible. As we have shown in this paper, human RP patients exhibit all
of the remodeling defects observed in models of RP which have
substantial import to most therapies.
4.10. Optogenetics
Optogenetics has been enthusiastically adopted as an experi-
mental approach and has substantial promise as a therapy for
vision rescue. While the implications for remodeling in opto-
genetics has recently been reviewed by (Henriksen et al., 2014),
optogenetically targeting remaining cell classes in the retina (Sahel
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cessing associated with remodeling that may alter processing of
signals from photosensitized cells.
Early targeting of surviving retinal bipolar cells may allow
preservation of retinal processing and many view bipolar cells as a
compromise between preserving as much of the retina's signal
networks as possible and the risk of cell loss late in degeneration.
However, there are several important limitations. Optogenetically
transducing large numbers of bipolar cells with current approaches
requires a subretinal injection which may induce more damage to
the neural retina due to the Müller cell seal, while phase II or III
remodeling may cause enough rewiring to distort processing. In
bipolar cells, one of the most commonly targeted cell types for
optogenetics, we know this is already a compromised pathway as
they become polyaxonal and engage in microneuromas before
progressing to cell death. Targeting of ganglion cells in late-stage
degeneration is appealing in those patients where bipolar or
amacrine cell death and remodeling may render upstream targets
unavailable (Jones et al., 2003; Marc and Jones, 2003; Marc et al.,
2003a, 2003b). However, we don't know whether or how long
the photic signals from optogenetically modiﬁed ganglion cells will
be able to overcome self-signaling from corrupt networks or even
when ganglion cell signaling no longer coherently signals visual
information to cortex due to upstream retinal remodeling.
Furthermore, it appears that all retinal neurons continue to die (e.g.
Fig. 9), and given the progressive nature of remodeling, it is likely
that optogenetically transduced neurons will be co-opted into
plasticity as the remodeling “program” continues. At the very least,
windows of opportunity that deﬁne when optogenetic in-
terventions will be possible or most successful need to be explored.
We argue that phase I or II retina is the most viable period. Further
complicating deﬁnition of temporal interventions, retinal remod-
eling is not coherent across retina and many forms of RP possess
regions of retina that are mixtures of phase II and III retina (Fig. 10).
Therefore, remodeling and cell death must be addressed if opto-
genetic rescues are to succeed.4.11. Gene therapy
Like optogenetics and survival factor therapies, gene therapy
approaches will also have to take into account progressive negative
plasticity in the retina as photoreceptors are lost and alterations in
Müller cells and neuronal networks follow. Windows of opportu-
nity will be important and different between individuals and will
require some means of monitoring patients, such as documenting
the presence of phase I retina by OCT. Administration of gene
therapy via subretinal injections is complicated by the emergence
of the glial seal in later phases of remodeling where again, surgical
detachment of the glial seal may be traumatic and likely do more
harm than good. Therefore, in late stage retinal degenerations,
intravitreal injections might be preferred, though this may not be
the ideal approach for many viral delivery schemes as targeting
therapies to penetrate the ILM.
Gene therapies that depend on photoreceptor survival will likely
be the most successful. However, it is clear that photoreceptor
involvement begins long before any obvious photoreceptor death.
The initial successes with gene therapy for Leber Congenital
Amurosis (LCA) have been stunning, but it a distinctly small per-
centage of retinal degenerative diseases. Furthermore, in the case of
LCA, it is clear that the retinal degeneration continues to progress
despite rescue of RPE65 (Jacobson et al., 2015) and it may be that
LCA and stationary night blindness that do not induce photore-
ceptor degeneration may still have restricted windows of oppor-
tunity for intervention, notably phase I of retinal remodeling.4.12. Survival factor therapy
Another strategy to retard retinal degeneration involves use of
survival factors such as neurotrophins (e.g. ciliary neurotrophic
factor, CNTF) to slow or delay photoreceptor apoptosis. These
strategies have been validated for slower models of adRP such as
the rat P23H and S344ter rhodopsin transgenic models (Sieving
et al., 2006), though some argue that structural preservation
afforded by CNTF does not necessarily include a functional rescue
(Liang et al., 2001). There is also evidence that CNTF infusion in
other models of RP negatively alters photoreceptor morphology
through loss of outer and inner segments and alters inner retinal
organization (Beltran et al., 2007). Therefore survival factor therapy
without known cellular or molecular targets and undeﬁned win-
dows of opportunity are not likely to be effective in the diverse
forms of human RP. Survival factors in of themselves currently offer
little prospect of reversing or altering the course of remodeling and
if effective, would be restricted to phase I and early phase II
remodeling. That said, ﬁnding generalizable targets that slow down
or delay cell death and/or the subsequent retinal remodeling are
attractive and may hold the best short term promise for preserving
vision.4.13. Stem/neuroprogenitor cell therapy
Several groups have shown that isolated stem/progenitor cells,
and possibly adult cells have the potential to integrate in the outer
nuclear layer and possibly repopulate the retina (Gust and Reh,
2011, Mansergh et al., 2015). This approach can take the form of
replacing lost cells or regenerating them and may hold incredible
promise for particularly RPE based therapies. But to date, the efﬁ-
ciency of cell integration in degenerate tissues is low unless the
remodeling process itself is restrained, as stem cells or transplanted
neuroprogenitors will not survive phase III remodeling. Addition-
ally, as discussed above, getting transplants past theMüller cell seal
is problematic and engineering exogenous photoreceptors to
extend synapses through the seal will be problematic. Direct in-
jection into the retina is also likely to activate microglial activation
which would inhibit migration (Singhal et al., 2008) or even result
in microglial attack (Bull et al., 2008). If stem and neuroprogenitor
cell therapies are to work and lead to new photoreceptor growth
and integration, they must establish connections with existing bi-
polar, horizontal and ganglion cells prior to onset of morphologic or
molecular remodeling. As such, most current RP patients will be
excluded and any stem or neuroprogenitor cell therapies will be
restricted to phase I and early phase II remodeling.4.14. Retinal transplantation
There have been efforts to deliver fetal retina sheets into the
remnant subretinal space of degenerating retina to rescue vision
loss. These efforts have demonstrated long-term photoreceptor
survival and some visual driving in rats (Seiler et al., 2012), though
retinal remodeling remains a major barrier. The glial seal, once
formedwill prevent easy retinal detachment and the extent (if any)
of transplant-to-host neurite intermingling is small (Seiler et al.,
2012). Furthermore, the transplanted retina begins to remodel
even more aggressively than the host retina (Seiler et al., 2012). If
phase 3 remodeling in the host retina ensues, an intact, or semi-
intact retinal transplant cannot recapitulate normal circuitry and
a functional outcome is impossible. Without understanding how to
constrain retinal remodeling, any retinal transplantation ap-
proaches will be largely restricted to phases I-II.
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There have been a number of efforts to restore vision to the
profoundly blind with both subretinal (Stingl et al., 2013) and
epiretinal bionic implants (Rizzo et al., 2014). The epiretinal im-
plants appear to be the most successful to date that provide direct
current stimulation of retinal ganglion cells or the broader retinal
circuitry. In late stage retinal degeneration shown in this paper, the
viability of such implants will be limited both in function and how
long they may be expected to stimulate a retina that is progres-
sively remodeling, especially if extensive neuronal death is present.
It has not been demonstrated that bionic implants of any kind ar-
rest retinal remodeling. In fact, there is some evidence that im-
plants induce further or more aggressive remodeling (Butterwick
et al., 2009).
It should also be noted that we don't have a fundamental,
detailed understanding of how signals ﬂow in the normal retina,
much less the degenerate retina. Even early in the retinal degen-
erative process, there is iGluR reprogramming of bipolar cell pop-
ulations that presumably alter the ON/OFF weighting of visual
pathways (Marc et al., 2007; Jones et al., 2011). Later in the retinal
degenerative process, retinal rewiring is more substantial with
novel synaptic formation between unknown classes of cells (Jones
et al., 2003). The likelihood that this synaptology is “normal” is low.
That said, a number of implanted patients can successfully navigate
with implants, at least for the near term. Regardless, if bionic im-
plants of the epiretinal or subretinal variety are to succeed in
providing a long term rescue, remodeling will have to be addressed
in these solutions as well.
5. Conclusions
RP is a primary sensory retina disease that converts to pro-
gressive neurodegenerative remodeling. Disease progression in
human RP shows that animal models of retinal degeneration
accurately recapitulate the human condition from early to late
stages of degeneration and remodeling. Cone mediated preserva-
tion of bipolar cell signaling, retinal reprogramming and retinal
remodeling seen in the human RP retina are all duplicated in ani-
mal models. Müller cell metabolic changes are also present
throughout degeneration both in animal models and human retina.
The mechanisms for negative plasticity in the neural retina are
unknown. If we are to understand the fundamental nature of
retinal plasticity and its impact on designing and implementing
strategies for rescue or arrest of vision loss, we need to explore
mechanisms of retinal remodeling. Understanding precisely how
retinas rewire at the earliest stages of retinal plasticity will deﬁne
how we intervene as these alterations serve as functional markers
for progression through various aspects of retinal disease that un-
fortunately, for diseases like RP and age-related macular degener-
ation AMD are both progressive and currently irreversible. A
fundamental problem with retinal degenerative diseases is the di-
versity of potential targets and complex specialization of various
cell classes as well as their cellecell connectivities and retinal
networks. Therefore, knowing which cell classes are involved, and
which anatomical structures are altered (gap junctions, adherens
junctions, synapses), as well as their physiological responses and
metabolic dependencies will provide additional molecular targets
for therapeutic interventions. Any therapy, bionic or biological, that
attempts to interface with a plastic and continuously revising
structure may have, at best, limited success.
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